Pulmonary hypertension in lymphangioleiomyomatosis: Characteristics in 20 patients

European Respiratory Journal

Volumn 40, Issue 3, 2012, Pages 630-640

  Cottin, Vincent ^a,b   Harari, Sergio ^c   Humbert, Marc ^d   Mal, Hervé ^e   Dorfmüller, Peter ^f   Jaïs, Xavier ^d   Reynaud Gaubert, Martine ^g,h   Prevot, Grégoire ⁱ   Lazor, Romain ^b,k   Taillé, Camille ^e   Lacronique, Jacques ^j   Zeghmar, Sabrina ^a,b   Simonneau, Gérald ^d   Cordier, Jean François ^a,b  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c San Giuseppe Hospital   (Italy)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e BICHAT HOSPITAL   (France)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^g HÔPITAL NORD   (France)

^h AIX MARSEILLE UNIVERSITÉ   (France)

ⁱ SERVICE DE PNEUMOLOGIE   (France)

^j Université Lyon I ^*  (France)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

Interstitial lung disease; Lymphangioleiomyomatosis; Pulmonary hypertension

Indexed keywords

CARBON MONOXIDE;

ADULT; AMBIENT AIR; ARTERIAL OXYGEN TENSION; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HEART INDEX; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LYMPHANGIOLEIOMYOMATOSIS; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; WALKING;

ADULT; BREATH TESTS; CARBON MONOXIDE; CARDIAC CATHETERIZATION; EXERCISE TEST; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; OXYGEN; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; VASCULAR RESISTANCE;

EID: 84865594877     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00093111     Document Type: Article

References (56)

1. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006; 27: 1056-1065. (Pubitemid 44911122)
2. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008; 133: 507-516. (Pubitemid 351272412)
3. Harari S, Torre O, Moss J. Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev 2011; 20: 34-44.
4. Cottin V, Archer F, Leroux C, et al. Milestones in lymphangioleiomyomatosis research. Eur Respir Rev 2011; 20: 3-6.
5. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
6. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26.
7. Reynaud-Gaubert M, Mornex JF, Mal H, et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation 2008; 86: 515-520.
8. Benden C, Rea F, Behr J, et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant 2009; 28: 1-7.
9. Boehler A, Speich R, Russi EW, et al. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996; 335: 1275-1280. (Pubitemid 26349269)
10. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis. Astudy of 69 patients. Groupe d'etudes et de recherche sur les maladies "orphelines" pulmonaires (GERM"O"P). Medicine (Baltimore) 1999; 78: 321-337.
11. Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59: 800-803. (Pubitemid 39215379)
12. Lazor R, Valeyre D, Lacronique J, et al. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004; 98: 536-541. (Pubitemid 38701858)
13. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-1874. (Pubitemid 39643992)
14. Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001; 164: 1072-1076. (Pubitemid 32971661)
15. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-633. (Pubitemid 29380683)
16. Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16: 460-463. (Pubitemid 27199604)
17. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
18. Tsangaris I, Orfanos S, Bouros D. Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification. Eur Respir J 2010; 35: 700-701.
19. Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007; 132: 1573-1578. (Pubitemid 350156015)
20. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002; 277: 30958-30967. (Pubitemid 34970798)
21. Krymskaya VP, Snow J, Cesarone G, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 2011; 25: 1922-1933.
22. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
23. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
24. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111. (Pubitemid 40847788)
25. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735. (Pubitemid 41448672)
26. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
27. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-522. (Pubitemid 41264217)
28. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
29. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
30. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55: 1052-1057.
31. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173: 105-111. (Pubitemid 43069795)
32. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663. (Pubitemid 46446854)
33. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-656. (Pubitemid 46446853)
34. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399. (Pubitemid 41507585)
35. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721. (Pubitemid 351194832)
36. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis. A review. Am J Pathol 1975; 79: 348-382.
37. Carrington CB, Cugell DW, Gaensler EA, et al. Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations. Am Rev Respir Dis 1977; 116: 977-995.
38. Montani D, Coulet F, Girerd B, et al. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore) 2011; 90: 201-211.
39. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194. (Pubitemid 40981192)
40. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced copd candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-1536. (Pubitemid 46218776)
41. Weitzenblum E, Delcroix M. Treatment of pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 313-324.
42. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
43. Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
44. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.
45. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161: 216-223. (Pubitemid 30055928)
46. Kiakouama L, Cottin V, Etienne-Mastroïanni B, et al. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J 2010; 36: 202-204.
47. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74. (Pubitemid 43106981)
48. Patel NM, Lederer DJ, Borczuk AC, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
49. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
50. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-593. (Pubitemid 41448654)
51. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
52. Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 2001; 25: 479-484. (Pubitemid 32240887)
53. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-278.
54. Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30: 914-921. (Pubitemid 351194795)
55. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1305-1310.
56. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740. (Pubitemid 36801751)